SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The January 2027 PDUFA date for z-rostudirsen is the near-term binary catalyst. Watch for any FDA advisory committee meeting announcement or briefing documents ahead of the decision. Also monitor Q1 2027 ACHIEVE topline data for z-basivarsen, which could support a BLA submission.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

DYN drug pipeline →

z-rostudirsen

▲ Bullish Named in this press release
Impact
Phase
Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
Time to market
Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
Next catalyst
PDUFA date · Jan 21, 2027 66d

What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$17.36
T+0 close · Nov 5, 2026 · via day close
Latest settled
−2.02%
T+5 · $17.01
Vs SPY
−5.31%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $17.36entry
  2. T+1 · 11d ago +4.09%α +3.78% · $18.07
  3. T+5 · 5d ago −2.02%α −5.31% · $17.01
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics reported Q3 2026 net loss of $193.6M ($1.06/share), wider than the $108.0M loss a year ago, driven by increased R&D and G&A spending ahead of potential z-rostudirsen launch. The key catalyst is the January 21, 2027 PDUFA date for z-rostudirsen in DMD and Q1 2027 topline data from the ACHIEVE registrational cohort for z-basivarsen in DM1. Cash of $1.134B is expected to fund operations into Q2 2028.

Key Financial Metrics

EPS
−$1.06

Key Facts

  • Q3 2026 net loss $193.6M ($1.06/share) vs $108.0M ($0.76/share) in Q3 2025
  • R&D expenses $161.7M, up from $97.2M YoY; G&A $35.3M, up from $16.7M YoY
  • Cash, equivalents and marketable securities $1.134B as of Sep 30, 2026
  • BLA for z-rostudirsen (DYNE-251) under FDA priority review; PDUFA date Jan 21, 2027
  • Topline data from ACHIEVE registrational expansion cohort for z-basivarsen (DYNE-101) expected Q1 2027
  • Potential U.S. launch of z-rostudirsen expected Q1 2027 if approved; z-basivarsen launch expected H1 2028
  • Four preclinical DMD programs (exons 44, 45, 53, 55) advancing

Financial Impact

Net loss widened by $85.5M YoY; cash burn rate increased; no revenue reported

net lossR&D expensesG&A expensescash position

Risk Factors

  • FDA may not approve z-rostudirsen by the PDUFA date or at all
  • ACHIEVE registrational cohort data may not support accelerated approval for z-basivarsen
  • Cash burn is accelerating; $1.134B may not be sufficient if launch is delayed or additional trials are needed
  • Competing DMD and DM1 therapies from other developers could limit commercial potential

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396308

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026